Let-7 family miRNAs have been well-documented to target HRAS to regulate self-renewal and tumorigenicity [41] and to sensitize KRAS mutant breast cancer to paclitaxel and gemcitabine [42]. The gene discussed is KRAS; the disease is breast carcinoma.